» Articles » PMID: 24603807

Adaptation of Pseudomonas Aeruginosa in Cystic Fibrosis Airways Influences Virulence of Staphylococcus Aureus in Vitro and Murine Models of Co-infection

Overview
Journal PLoS One
Date 2014 Mar 8
PMID 24603807
Citations 86
Authors
Affiliations
Soon will be listed here.
Abstract

Cystic fibrosis (CF) airways disease represents an example of polymicrobial infection whereby different bacterial species can interact and influence each other. In CF patients Staphylococcus aureus is often the initial pathogen colonizing the lungs during childhood, while Pseudomonas aeruginosa is the predominant pathogen isolated in adolescents and adults. During chronic infection, P. aeruginosa undergoes adaptation to cope with antimicrobial therapy, host response and co-infecting pathogens. However, S. aureus and P. aeruginosa often co-exist in the same niche influencing the CF pathogenesis. The goal of this study was to investigate the reciprocal interaction of P. aeruginosa and S. aureus and understand the influence of P. aeruginosa adaptation to the CF lung in order to gain important insight on the interplay occurring between the two main pathogens of CF airways, which is still largely unknown. P. aeruginosa reference strains and eight lineages of clinical strains, including early and late clonal isolates from different patients with CF, were tested for growth inhibition of S. aureus. Next, P. aeruginosa/S. aureus competition was investigated in planktonic co-culture, biofilm, and mouse pneumonia model. P. aeruginosa reference and early strains, isolated at the onset of chronic infection, outcompeted S. aureus in vitro and in vivo models of co-infection. On the contrary, our results indicated a reduced capacity to outcompete S. aureus of P. aeruginosa patho-adaptive strains, isolated after several years of chronic infection and carrying several phenotypic changes temporally associated with CF lung adaptation. Our findings provide relevant information with respect to interspecies interaction and disease progression in CF.

Citing Articles

Polymicrobial infection in cystic fibrosis and future perspectives for improving Mycobacterium abscessus drug discovery.

Baker E, Allcott G, Cox J NPJ Antimicrob Resist. 2025; 2(1):38.

PMID: 39843836 PMC: 11721438. DOI: 10.1038/s44259-024-00060-5.


Polymicrobial interactions between and promote biofilm formation and persistence in chronic wound infections.

Keim K, Bhattacharya M, Crosby H, Jenul C, Mills K, Schurr M bioRxiv. 2024; .

PMID: 39574578 PMC: 11580920. DOI: 10.1101/2024.11.04.621402.


Impact of mixed Staphylococcus aureus-Pseudomonas aeruginosa biofilm on susceptibility to antimicrobial treatments in a 3D in vitro model.

Landa G, Clarhaut J, Buyck J, Mendoza G, Arruebo M, Tewes F Sci Rep. 2024; 14(1):27877.

PMID: 39538008 PMC: 11561256. DOI: 10.1038/s41598-024-79573-y.


Interspecies interactions alter the antibiotic sensitivity of .

Koumans C, Tandar S, Liakopoulos A, van Hasselt J Microbiol Spectr. 2024; :e0201224.

PMID: 39495005 PMC: 11619387. DOI: 10.1128/spectrum.02012-24.


Modeling Cystic Fibrosis Chronic Infection Using Engineered Mucus-like Hydrogels.

OBrien C, Spencer S, Jafari N, Huang A, Scott A, Cheng Z ACS Biomater Sci Eng. 2024; 10(10):6558-6568.

PMID: 39297972 PMC: 11483100. DOI: 10.1021/acsbiomaterials.4c01271.


References
1.
Jarry T, Cheung A . Staphylococcus aureus escapes more efficiently from the phagosome of a cystic fibrosis bronchial epithelial cell line than from its normal counterpart. Infect Immun. 2006; 74(5):2568-77. PMC: 1459703. DOI: 10.1128/IAI.74.5.2568-2577.2006. View

2.
Montanari S, Oliver A, Salerno P, Mena A, Bertoni G, Tummler B . Biological cost of hypermutation in Pseudomonas aeruginosa strains from patients with cystic fibrosis. Microbiology (Reading). 2007; 153(Pt 5):1445-1454. DOI: 10.1099/mic.0.2006/003400-0. View

3.
Liberati N, Urbach J, Miyata S, Lee D, Drenkard E, Wu G . An ordered, nonredundant library of Pseudomonas aeruginosa strain PA14 transposon insertion mutants. Proc Natl Acad Sci U S A. 2006; 103(8):2833-8. PMC: 1413827. DOI: 10.1073/pnas.0511100103. View

4.
Sibley C, Parkins M, Rabin H, Duan K, Norgaard J, Surette M . A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. Proc Natl Acad Sci U S A. 2008; 105(39):15070-5. PMC: 2567494. DOI: 10.1073/pnas.0804326105. View

5.
Doring G, Hoiby N . Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros. 2004; 3(2):67-91. DOI: 10.1016/j.jcf.2004.03.008. View